Get the Complete Picture

Ambry Genetics®
A Konica Minolta Company



Clearly determine patients who may benefit from treatment with PARP inhibitors and simultaneously understand hereditary risk.

TUMORNEXT-*HRD*
Detects and differentiates between germline and somatic mutations in homologous recombination repair genes including *BRCA1* and *BRCA2* in one simple test

GERMLINE (HEREDITARY)

IDENTIFY OVARIAN CANCER PATIENTS:

- Who are at increased risk for other cancers
- Who have family members with a significantly increased risk for cancer and clarify screening recommendations

TUMOR (SOMATIC)

IDENTIFY UP TO 2X AS MANY PATIENTS*:

- Who may benefit from targeted treatment with PARP inhibitors[1,2]
- Increase diagnostic yield by including methylation status, including additional HRD genes

** versus BRCA-only testing*

WHY ORDER TUMORNEXT-*HRD*?

GET MORE COMPLETE INFORMATION TO GUIDE HEALTHCARE DECISIONS WITH ONE TEST

Tests that look at only tumor tissue do not allow you to identify patients with hereditary cancer and those that look at only germline will miss patients who may benefit from PARP inhibitors. TumorNext-*HRD* does both.

Ambry Genetics®
A Konica Minolta Company

Why TumorNext-*HRD*?

- NCCN® recommends *BRCA1/2* germline testing for all patients with epithelial ovarian cancer[3]
- SGO recommends that all women diagnosed with epithelial ovarian, fallopian tube, and peritoneal cancers should consider genetic testing, even in the absence of a family history of cancer[4]
- Identifying patients who may benefit from PARP inhibitor treatment, or future eligibility

One test looks at both tumor and germline to bring more complete data to your practice.

TEST DETAILS

TUMORNEXT-*HRD*

Paired tumor/germline analysis of *BRCA1/BRCA2* plus 9 additional genes** in the homologous recombination repair pathway that are also known to be associated with hereditary cancer, and also includes *BRCA1* and *RAD51C* methylation analysis.

ALSO AVAILABLE: TUMORNEXT-*BRCA*

Analyzes *BRCA1* and *BRCA2* in both normal tissue (blood or saliva) and ovarian tumor tissue

Turnaround Time

21-28 days (once both samples are received)

Specimen Requirements

Both tumor and normal sample are required* for testing. Visit ambrygen.com/specimen-requirements for complete details.

** Pathology report also required with order*
*** Additional genes on TumorNext-HRD: ATM, BARD1, BRIP1, CHEK2, MRE11A, NBN, PALB2, RAD51C, RAD51D*

ORDERING PROCESS

1. Complete Tumor Test Requisition Form (TRF) and submit with blood sample and relevant pathology report (required)
2. Ambry will contact the pathology department to request the tumor specimen
3. Testing will begin when the blood and tumor samples are both received; both are required for processing

Please note that the time to receive the tumor specimen depends on individual pathology departments and may delay testing. Follow-up may be needed.

References

1. Hennessy BTJ, *et al.* JCO. 2010
2. Pennington KP *et al.* Clin Cancer Res 2013
3. NCCN Clinical Practice Guidelines in Oncology®. Genetic/Familial High-Risk Assessment: Breast and Ovarian. V1.2017
4. SGO Clinical Practice Statement: Genetic Testing for Ovarian Cancer. October 2014

15 Argonaut, Aliso Viejo, CA 92656 USA Toll Free +1 866 262 7943 Fax +1 949 900 5501 ambrygen.com